TY - JOUR
T1 - MRSA infections among patients in the emergency department
T2 - A European multicentre study
AU - Bouchiat, C.
AU - Curtis, S.
AU - Spiliopoulou, I.
AU - Bes, M.
AU - Cocuzza, C.
AU - Codita, I.
AU - Dupieux, C.
AU - Giormezis, N.
AU - Kearns, A.
AU - Laurent, F.
AU - Molinos, S.
AU - Musumeci, R.
AU - Prat, C.
AU - Saadatian-Elahi, M.
AU - Tacconelli, E.
AU - Tristan, A.
AU - Schulte, B.
AU - Vandenesch, F.
AU - Monneuse, Olivier
AU - de Francisco, Toni
AU - Casella, Pietro
AU - Erbizzoni, Serena
AU - Melzi, Sara
AU - Oggioni, Davide
AU - Sala, Roberta
AU - Calaresu, Enrico
AU - Efthimia, Petinaki
AU - Markos, Marangos
AU - Petinaki, Efthimia
AU - Schroeder, Wiebke
N1 - Funding Information:
We acknowledge Helene Meugnier and Taissia-Lelekov Boissard for technical support. Part of this work was presented as on oral communication at the European Congress of Clinical Microbiology and Infectious Diseases in Amsterdam in April 2016 (Abstract number 826). The following investigators participated in the study: Olivier Monneuse, Hospices Civils de Lyon, France; Toni de Francisco, Badalona, Spain; Pietro Casella, Serena Erbizzoni, Sara Melzi and Davide Oggioni, Vimercate, Italy; Roberta Sala, Desio, Italy; Enrico Calaresu, Monza, Italy; Petinaki Efthimia, School of Medicine, University of Thessaly, Larissa, Greece; Marangos Markos, School of Medicine, University of Patras, Greece; Efthimia Petinaki University of Thessaly, Larissa, Greece; Wiebke Schroeder, University Hospital of Tuebingen, Germany. This study was conducted as part of our routine work.
Publisher Copyright:
© The Author 2016.
PY - 2017/2
Y1 - 2017/2
N2 - Background: MRSA is a therapeutic concern worldwide, and a major agent of community-acquired skin and soft tissue infections (CA-SSTIs). While the US epidemiology of MRSA in CA-SSTIs is well described and reports the high prevalence of the USA300 clone, data on the European situation are lacking. Objectives: To determine the prevalence and clonal characteristics of MRSA in CA-SSTIs in seven European emergency departments. Patients and methods: From April to June 2015, patients presenting to the tertiary hospital emergency department with a Staphylococcus aureus CA-SSTI were prospectively enrolled. S. aureus isolates were characterized by antimicrobial susceptibility testing, detection of Panton-Valentine leucocidin encoding genes and spa-typing, MLST and/or DNA microarray. Results: Two-hundred and five cases of S. aureus-associated CA-SSTIs were included, comprising folliculitis, furuncles, abscesses, paronychia, impetigo, carbuncles and cellulitis. Of the 205 cases, we report an MRSA prevalence rate of 15.1%, with a north (0%) to south (29%) increasing gradient. Fifty-one isolates were Panton-Valentine leucocidin-positive (24.9%), whether MSSA or MRSA, with a heterogeneous distribution between countries. Clonal distribution of MSSA and MRSA showed high diversity, with no predominant circulating clone and no archetypical USA300 CA-MRSA clone. Conclusions: This original prospective multicentre study highlights stark differences in European MRSA epidemiology compared with the USA, and that the USA300 CA-MRSA clone is not predominant among communityinfected patients in Europe.
AB - Background: MRSA is a therapeutic concern worldwide, and a major agent of community-acquired skin and soft tissue infections (CA-SSTIs). While the US epidemiology of MRSA in CA-SSTIs is well described and reports the high prevalence of the USA300 clone, data on the European situation are lacking. Objectives: To determine the prevalence and clonal characteristics of MRSA in CA-SSTIs in seven European emergency departments. Patients and methods: From April to June 2015, patients presenting to the tertiary hospital emergency department with a Staphylococcus aureus CA-SSTI were prospectively enrolled. S. aureus isolates were characterized by antimicrobial susceptibility testing, detection of Panton-Valentine leucocidin encoding genes and spa-typing, MLST and/or DNA microarray. Results: Two-hundred and five cases of S. aureus-associated CA-SSTIs were included, comprising folliculitis, furuncles, abscesses, paronychia, impetigo, carbuncles and cellulitis. Of the 205 cases, we report an MRSA prevalence rate of 15.1%, with a north (0%) to south (29%) increasing gradient. Fifty-one isolates were Panton-Valentine leucocidin-positive (24.9%), whether MSSA or MRSA, with a heterogeneous distribution between countries. Clonal distribution of MSSA and MRSA showed high diversity, with no predominant circulating clone and no archetypical USA300 CA-MRSA clone. Conclusions: This original prospective multicentre study highlights stark differences in European MRSA epidemiology compared with the USA, and that the USA300 CA-MRSA clone is not predominant among communityinfected patients in Europe.
UR - https://www.scopus.com/pages/publications/85014580235
U2 - 10.1093/jac/dkw431
DO - 10.1093/jac/dkw431
M3 - Article
C2 - 27798212
AN - SCOPUS:85014580235
SN - 0305-7453
VL - 72
SP - 372
EP - 375
JO - Journal of Antimicrobial Chemotherapy
JF - Journal of Antimicrobial Chemotherapy
IS - 2
ER -